Evidence map›Paper›PMID 38990519›Full record

ArticleAnalytical chemistry2024

Accurate Collisional Cross Section Measurement by Multipass Cyclic Ion Mobility Spectrometry.

Chaoshuang Xia, Elias Mernie, Joseph Zaia, Catherine E Costello, Cheng Lin

Abstract read
In one paragraph

Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chaoshuang XiaDepartment of Biochemistry & Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States.ORCID 0000-0001-7076-4813
Elias MernieDepartment of Biochemistry & Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States.
Joseph ZaiaDepartment of Biochemistry & Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States.ORCID 0000-0001-9497-8701
Catherine E CostelloDepartment of Biochemistry & Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States.ORCID 0000-0003-1594-5122
Cheng LinDepartment of Biochemistry & Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States.ORCID 0000-0003-3653-9633

Funding

Selecting HA glycosylation for improved vaccine responsesR01AI155975 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WAN, XIUFENG HENRY, WOODS, ROBERT J · 2021 to 2025
$4.0M
Methods for measuring matrisome molecule similarity during disease processesR35GM144090 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JOSEPH ZAIA · 2022 to 2026
$2.1M
Legacy Support During Closure of the Mass Spectrometry Resource for Biology and MedicineR24GM134210 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2019 to 2021
$2.1M
High-Throughput De Novo Glycan SequencingR01GM132675 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HONG, PENGYU, LIN, CHENG · 2019 to 2022
$2.0M
Methods for determination of glycoprotein glycosylation similarities among disease statesR01GM133963 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2019 to 2021
$1.4M
A Thermo-Fisher Scientific Q-Exactive HF Mass Spectrometry SystemS10OD021651 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2016 to 2016
$580k
NIAID NIH HHS R01 AI155975NIGMS NIH HHS R01 GM132675NIGMS NIH HHS R01 GM133963NIGMS NIH HHS R24 GM134210NIGMS NIH HHS R35 GM144090NIH HHS S10 OD021651
6 · The paper itself

Abstract

Ion mobility-mass spectrometry (IM-MS) is a powerful analytical tool for structural characterization. IM measurement provides collision cross section (CCS) values that facilitate analyte identification. While CCS values can be directly calculated from mobility measurements obtained using drift tube ion mobility spectrometry (DT-IMS), this method has limited mobility resolution due to the practical constraints on the length of the ion drift path. Consequently, DT-IMS cannot differentiate analytes with similar mobilities or resolve fine mobility features of individual ions. Cyclic IMS (cIMS) instruments leverage a cyclic path enabled by traveling wave ion mobility (TWIM) technology and offer increased mobility solution to address this challenge. While TWIM devices must first be calibrated to enable CCS measurements, current calibration strategies are primarily tailored for single-pass analyses. This preference is partly attributed to the challenges associated with multipass calibration methods, which require both calibrants and analytes to experience the same number of passes. Achieving this consistency can be complicated due to factors like peak splitting and diffusion, and may not be feasible for online IM-MS analyses. A recent report employed average ion velocities obtained from multiple measurements under different separation pathlengths as a path length-independent metric for CCS calibration. However, the ability to exploit this averaging approach is limited by observed variation in ion drift time/velocity in these measurements. In this study, we introduce a novel calibration strategy designed for multipass cIMS analyses, directly targeting the root cause for the path length- and mobility-dependent variations in ion drift time. With this method, we demonstrate that CCS values derived from multipass measurements closely align with those obtained from single-pass analyses, with an average deviation of 0.1%. We apply this method to characterize four isomeric trisaccharides. Our approach not only results in excellent agreement between our measured

Identifiers

PMID38990519
PMCPMC11682735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.